18 de marzo de 2019
31 de julio de 2014

EMA Approves Eisai's Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid

Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:


- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
management
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Iceland, Ireland, Italy, the Middle East, the Netherlands, Norway, Portugal, Russia, Slovakia, Spain, Switzerland, Sweden, and the United Kingdom.

For further information please visit our web site: http://www.eisai.co.uk

References

1. Brito J et al. BMJ 2013; 347

2. Thyroid Cancer. International Agency for Research on Cancer. http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=35 (last accessed: July 2014)

3. Data on file, Eisai.Co.Ltd

4. Zuccotto F et al. J. Med. Chem. 2010, 53, 2681-2694.

5. Liao et al. Journal of Medicinal Chemistry, 2007, 50;3:409-422

6. Schlumberger M et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). ASCO 2014 abstract #E450

7. Matsui J, et al. Clin Cancer Res 2008;14:5459-65

8. Matsui J, et al. Int J Cancer 2008;122:664-71

9. National Cancer Institute at the National Institute of Health http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Patient/page1/AllPages#1 (last accessed: July 2014)

10. Cooper DS et al. Thyroid. 2009;19(11):1167-1214

11. Thyroid Cancer Basics. 2011. http://www.thyca.org

12. Gild M et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews Endocrinology. 2011; 7: 617-624

13. Bible K, et al. Lancet Oncology 2010;11(10):962-972

Job code: Lenvatinib-UK0032

Date of preparation: July 2014

CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Ben Speller, 31 Jul. (0) - 7908-314-155 / +44(0)7908-409416, Cressida_Robson@eisai.net,Ben_Speller@eisai.net; Tonic Life Communications: Siobhan Reilly / AprilKenneally, +44(0)207-798-9999 / +44(0)207-798-9263,siobhan.reilly@toniclc.com, april.kenneally@toniclc.com